# Jair Bar

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/jair-bar/

## Facts

| Field | Value |
| --- | --- |
| Citations | 10,489 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 41 |
| i10-index | 97 |
| Last Known Institution | Tel Aviv University |
| OpenAlex ID | https://openalex.org/A5004732154 |
| ORCID iD | 0000-0002-1224-3646 |
| Works | 321 |

## Researcher papers

- [The human tumor microbiome is composed of tumor type–specific intracellular bacteria](https://scholariq.org/papers/the-human-tumor-microbiome-is-composed-of-tumor-type-specific-intracellular/)
- [Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/durvalumab-plus-platinum-etoposide-versus-platinum-etoposide-in-first-line/)
- [Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/durvalumab-with-or-without-tremelimumab-plus-platinum-etoposide-versus-platinum/)
- [Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study](https://scholariq.org/papers/treatment-characteristics-and-real-world-progression-free-survival-in-patients/)
- [BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors](https://scholariq.org/papers/braf-mutant-lung-cancer-programmed-death-ligand-1-expression-tumor-mutational/)
- [The interaction of CD4+ helper T cells with dendritic cells shapes the tumor microenvironment and immune checkpoint blockade response](https://scholariq.org/papers/the-interaction-of-cd4-helper-t-cells-with-dendritic-cells-shapes-the-tumor/)
- [Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage–SCLC: Results From the Phase 3 MERU Study](https://scholariq.org/papers/rovalpituzumab-tesirine-as-a-maintenance-therapy-after-first-line-platinum-based/)
- [Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous <i>EGFR</i> -Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial](https://scholariq.org/papers/telisotuzumab-vedotin-monotherapy-in-patients-with-previously-treated-c-met/)
- [Interferon-stimulated neutrophils as a predictor of immunotherapy response](https://scholariq.org/papers/interferon-stimulated-neutrophils-as-a-predictor-of-immunotherapy-response/)
- [Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i> –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer](https://scholariq.org/papers/phase-iii-keynote-789-study-of-pemetrexed-and-platinum-with-or-without/)
- [Transformation to small cell lung cancer as a mechanism of resistance to immunotherapy in non-small cell lung cancer](https://scholariq.org/papers/transformation-to-small-cell-lung-cancer-as-a-mechanism-of-resistance-to/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Tel Aviv University](https://scholariq.org/institutions/tel-aviv-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.